Results 121 to 130 of about 20,100 (304)

Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome [PDF]

, 2016
The role of complement in the atypical form of hemolytic uremic syndrome (aHUS) has been investigated extensively in recent years. As the HUS-associated bacteria Shiga-toxin-producing Escherichia coli (STEC) can evade the complement system, we ...
Anja Roos, Annelies Jeronimus-Klaasen, Antonia H. M. Bouts, Dineke Westra, Eiske M. Dorresteijn, Elena B. Volokhina, Jaap A. Bakker, Joanna A. E. van Wijk, Joop Goertz, Lambert P. van den Heuvel, Mandy G. Keijzer-Veen, Nicole C. A. J. van de Kar, Renate G. van der Molen, Thea J. A. M. van der Velden, Valentina Gracchi   +14 more
core   +2 more sources

Linking preclinical models to clinical realities: VEGF/VEGFR inhibitors and thrombotic microangiopathy in cancer therapy

iMetaOmics, Volume 2, Issue 2, June 2025.
This study investigates the risk of thrombotic microangiopathy (TMA) induced by vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) inhibitors in cancer therapy. Using data from the FDA Adverse Event Reporting System (FAERS), the WHO Global Database for Adverse Drug Reactions (Vigibase), and The Cancer ...
Aimin Jiang, Zhanzhi Li, Ying Liu, Junyi Shen, Quan Cheng, Anqi Lin, Peng Luo, Linhui Wang   +7 more
wiley   +1 more source

Paroxysmal nocturnal hemoglobinuria and eculizumab

Haematologica, 2010
Paroxysmal nocturnal hemoglobinuria (PNH) is enough of a tongue-twister for patients and doctors alike and we all teach the students that PNH is a disorder characterized by the triad of intravascular hemolysis, venous thrombosis and cytopenias.[1][1]–[3][2] But in this journal, founded by ...
Lucio Luzzatto, Antonio M. Risitano, Rosario Notaro   +2 more
openaire   +3 more sources

Effectiveness of Iptacopan Versus C5 Inhibitors in Complement Inhibitor‐Naive Patients With Paroxysmal Nocturnal Haemoglobinuria

eJHaem, Volume 6, Issue 3, June 2025.
ABSTRACT Background Paroxysmal nocturnal haemoglobinuria (PNH) is characterised by haemolytic anaemia, bone marrow failure and thrombosis. The single‐arm phase 3 APPOINT‐PNH trial (NCT04820530) investigating iptacopan monotherapy in complement inhibitor‐naive patients demonstrated significant haemoglobin concentration improvements.
Matthew Holt, Richard J. Kelly, Jilles M. Fermont, Soudeh Ansari, Marion Dahlke, Isabelle Brindel, Lynda Maafa, Flore Sicre de Fontbrune, Régis Peffault de Latour   +8 more
wiley   +1 more source

Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria

Haematologica, 2020
Eculizumab is first-line treatment for paroxysmal nocturnal hemoglobinuria (PNH); however, approximately 11%-27% of patients may experience breakthrough hemolysis (BTH) on approved doses of eculizumab.
Robert A. Brodsky, Régis Peffault de Latour, Scott T. Rottinghaus, Alexander Röth, Antonio M. Risitano, Ilene C. Weitz, Peter Hillmen, Jaroslaw P. Maciejewski, Jeff Szer, Jong Wook Lee, Austin G. Kulasekararaj, Lori Volles, Andrew I. Damokosh, Stephan Ortiz, Lori Shafner, Peng Liu, Anita Hill, Hubert Schrezenmeier   +17 more
doaj   +1 more source

Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis

Therapeutic Advances in Neurological Disorders, 2020
Background: Eculizumab is a humanized monoclonal antibody that targets complement protein C5 and inhibits terminal complement-mediated damage at the neuromuscular junction.
Munenori Oyama, Kensuke Okada, Masayuki Masuda, Yuko Shimizu, Kazumasa Yokoyama, Akiyuki Uzawa, Naoki Kawaguchi, Ryotaro Ikeguchi, Yasunobu Hoshino, Taku Hatano, Yukiko Ozawa, Jin Nakahara, Hitoshi Aizawa, Kazuo Kitagawa, Nobutaka Hattori, Satoshi Kuwabara, Hiroyuki Murai, Shigeaki Suzuki   +17 more
doaj   +1 more source

Epi Update for Friday, July 14, 2017 [PDF]

, 2017
Weekly Newsletter for the Center for Acute Disease Epidemiology of the Iowa Department of Public ...

core  

Eculizumab [PDF]

British Journal of Clinical Pharmacology, 2009
Eline A, Dubois, Adam F, Cohen
openaire   +2 more sources

A Transfusion Reaction due to Anti‐ER5 in a Hyposplenic β0 Thalassemia Major Patient

American Journal of Hematology, Volume 100, Issue 6, Page 1074-1075, June 2025.
Arun Thomas, Kirstin Lund, Viviene Ballon, Barbara J. Bain   +3 more
wiley   +1 more source

Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern

Case Reports in Nephrology, 2016
In patients with atypical hemolytic uremic syndrome (aHUS), complement blocking by eculizumab rapidly halts the process of thrombotic microangiopathy and it is associated with clear long-term hematologic and renal improvements.
Camino García Monteavaro, Carmen Peralta Roselló, Borja Quiroga, José María Baltar Martín, Lorena Castillo Eraso, Fernando de Álvaro Moreno, Alberto Martínez Vea, María Teresa Visus-Fernández de Manzanos   +7 more
doaj   +1 more source